Iliad Biotechnologies, LLC is a New York-based company dedicated to addressing the global health challenge of pertussis, also known as whooping cough. With a focus on prevention and treatment, their team of experts is committed to developing innovative live vaccines and vector platforms to combat the B. pertussis bacteria, aiming to reduce the significant morbidity and mortality associated with this highly contagious disease.
Driven by a clear mission, Iliad Biotechnologies aims to make a substantial impact on the pertussis landscape, which claims the lives of 200,000 individuals and affects 16 million people worldwide each year. Through their cutting-edge scientific research and development, they strive to provide effective solutions for all age groups, from infants to adults, in order to prevent colonization and transmission of the B. pertussis bacteria.
Generated from the website